As part of the Obama administration’s healthcare reform, patients will, for the first time, be able to see what money pharmaceutical companies are paying to physicians and how – every notepad, free trial and conference junket. Reporters Charles Ornstein and Tracy Weber have, over the last 18 months, have been engaged in a kind of dry run, following a money trail that 13 pharma companies were legally required to disclose.There were a few parts of this segment that I thought could lead to interesting research projects...
The first was pretty obvious, which is how news consumers (aka: patients) would actually read, make sense of, and (potentially) act on information provided by journalists. Databases provided by news organizations can be amazing resources, but even the best-designed systems can be pretty complicated. How readers use the raw data (however that might be provided), as well as whatever stories the journalists produce using that data, would be pretty interesting. I'd have to imagine readers' health literacy would play a role there, of course. It takes a pretty media- and health-savvy consumer to really dig into this and fully understand the implications, I suspect.
The other thing that I thought was surprising was the healthcare providers that can write prescriptions but AREN'T covered by these kinds of agreements meant to provide extra sunshine on how pharma companies pay physicians to give speeches and such. They noted in the stories that other healthcare providers with prescriptive authority (e.g., nurse practitioners) aren't included. If pharma companies believe these kinds of payments do influence prescription decisions, will the funding shift to these non-covered healthcare providers? The view of nurse practitioners is pretty limited in academic literature on DTC prescription drug advertising (compared to physicians or patients), and this just got me thinking about how other healthcare providers merit more attention given these kinds of stories.

